Ahh, he speaks again! Once more, as I know you struggle with...

Ahh, he speaks again! Once more, as I know you struggle with reality the older you get

CP1 still has the lowest burn rate of any cannabinoid biotech and remains the only one still fully funded through non-dilutive funding with a market-leading partner. A milestone most bio-techs never reach, let alone in this sector. That’s what success actually looks like. Please, show us something to the contrary, we'll wait?

And AC8? Oh, you mean the other company that had already burned through $50 million before Layton ‘came and sipped tea’, because of you and your mates? Let’s take another quick look through the financials the following year (see, this is what we love about facts - very hard to argue). Corporate overheads down by $1.1m, employee expenses by $1.75m. Or, in percentage terms (since with a name like jcurve, you want people to think 'you're good with numbers') a 76%, and 72% drop, respectively.

Sorry, what was that about money being ‘pissed away’?